SCHEMBL20153219

SCHEMBL20153219

COc1ccc(CN2C3CC2CN(C)C3)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.54
RET P07949 2/20 0.45
DRD4 P21917 4/20 0.44
MAOB P27338 2/20 0.43
KDM1A O60341 1/20 0.43
MAOA P21397 1/20 0.43
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CCR3 P51677 1/20 0.41
KDM4E B2RXH2 1/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ATM Q13315 1/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
PDE2A O00408 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20071141 0.87 SIGMAR1 (0.51) SIGMAR1RETDRD4MAOBKDM1A
SCHEMBL20071140 0.86 SIGMAR1 (0.50) SIGMAR1RETDRD4MAOBKDM1A
SCHEMBL20069798 0.85 SIGMAR1 (0.55) SIGMAR1DRD4MAOBKDM1AMAOA
SCHEMBL22811975 0.84 SIGMAR1 (0.54) SIGMAR1RETDRD4MAOBKDM1A
SCHEMBL23555159 0.84 SIGMAR1 (0.48) SIGMAR1RETDRD4MAOBKDM1A
SCHEMBL20154601 0.76 RET (0.50) RETHCRTR1HCRTR2
SCHEMBL22031236 0.74 L3MBTL1 (0.53) SIGMAR1RETALDH1A1MEN1KMT2A
SCHEMBL20071150 0.73 HCRTR1 (0.47) SIGMAR1RETHCRTR1HCRTR2PDE2A
SCHEMBL18390147 0.73 CHRM2 (0.58) SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL20070542 0.72 RET (0.45) SIGMAR1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF SIGMAR1 3863/4885RET 1/4885DRD4 2839/4885
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF SIGMAR1 3863/4885RET 1/4885DRD4 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.